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Summary
The parasitic protozoan Toxoplasma gondii, the causal agent of toxoplasmosis, can infect most
mammals and birds. In human medicine, T. gondii can cause complications in pregnant women
and immunodeficient individuals, while in veterinary medicine, T. gondii infection has economic
importance due to abortion and neonatal loss in livestock. Thus, the development of an effective
anti-Toxoplasma vaccine would be of great value. In this study, we analysed the expression of
T. gondii GRA4 antigen by chloroplast transformation (chlGRA4) in tobacco plants and evaluated
the humoral and cellular responses and the grade of protection after oral administration of
chlGRA4 in a murine model. The Western blot analysis revealed a specific 34-kDa band mainly
present in the insoluble fractions. The chlGRA4 accumulation levels were approximately 6 lg/g
of fresh weight (equivalent to 0.2% of total protein). Oral immunization with chlGRA4 resulted
in a decrease of 59% in the brain cyst load of mice compared to control mice. ChlGRA4
immunization elicited both a mucosal immune response characterized by the production of
specific IgA, and IFN-c, IL-4 and IL-10 secretion by mesenteric lymph node cells, and a systemic
response in terms of GRA4-specific serum antibodies and secretion of IFN-c, IL-4 and IL-10 by
splenocytes. Our results indicate that oral administration of chlGRA4 promotes the elicitation of
both mucosal and systemic balanced Th1/Th2 responses that control Toxoplasma infection,
reducing parasite loads.
Introduction
The parasitic protozoan Toxoplasma gondii, the causal agent of
toxoplasmosis, can infect most mammals and birds (Tenter et al.,
2000). Toxoplasma gondii is recognized as a category B priority
pathogen by the National Institute of Health, Bethesda, USA. In
humans, T. gondii infection is widespread, and for most people,
the parasite causes an asymptomatic infection. However, T. gon-
dii can cause complications in pregnant women and immunode-
ficient individuals (Mitchell et al., 1990; Luft and Remington,
1992; Rorman et al., 2006). Also, recent studies have shown that
chronic T. gondii infections can induce neuropsychiatric disorders
such as schizophrenia (Flegr, 2007; Pedersen et al., 2011).
Transmission to humans is either through consumption of food
contaminated with tissue cysts and meat products from infected
animals or by ingestion of oocysts released in the faeces of
infected cats (Hill and Dubey, 2002). In veterinary medicine,
T. gondii infection has economic importance due to abortion and
neonatal loss in livestock (Dubey, 2004, 2009). Indeed, millions of
productive lambs are lost through this infectious disease (Dubey,
2009). On the other hand, treatment of toxoplasmosis is difficult
due to the toxic effects of available drugs, and re-infection also
occurs rapidly. Thus, the development of either an effective
vaccine or new anti-Toxoplasma drugs would be of great value to
human and veterinary medicine (Henriquez et al., 2010).
In recent years, significant advances have been made in
identifying possible new vaccines that can induce a protective
immune response against this parasite. For example, excretory/
secretory antigens of T. gondii have been shown to play an
important role in stimulating immune responses to T. gondii
(Cesbron-Delauw, 1994). The main components of the excretory/
secretory fraction are the dense granule (GRA) proteins (Cesbron-
Delauw, 1994). In particular, GRA4 appears as an interesting
component for the development of an anti-Toxoplasma multian-
tigenic vaccine, which could be based either on DNA or on
recombinant proteins (Martin et al., 2004; Mevelec et al., 2005;
Zhang et al., 2007; Sa´nchez et al., 2011). Its sequence contains a
linear epitope that is highly antigenic (Mevelec et al., 1998).
Indeed, GRA4 is an effective promoter of the expression of IgA
and IgG antibodies (Mevelec et al., 1998; Nigro et al., 2003;
Altcheh et al., 2006). Also, immunization with DNA or recombi-
nant GRA4 is able to induce a cellular response with accumulation
of IFN-c (Desolme et al., 2000; Mevelec et al., 2005; Sa´nchez
et al., 2011). On the other hand, oral immunization of C57BL/6
(H-2d) mice with truncated soluble forms of GRA4 in association
with cholera toxin induces a significant Th2-like mucosal response
and partial resistance to oral infection with T. gondii (Mevelec
et al., 1998). These results indicate that GRA4 is a potential
candidate for oral vaccination against T. gondii, able to induce
both mucosal and systemic immune responses.
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The production of plant-derived vaccines has been widely
assayed in the last 20 years. Several antigens from human and
animal pathogens have been correctly expressed and shown to
produce a specific humoral response, and in some cases, a
protective response against infection in murine models (Kong
et al., 2001; Clemente et al., 2005; Go´mez et al., 2008; Santi
et al., 2008; Kostrzak et al., 2009; Zhang et al., 2009; Laguı´a
Becher et al., 2010; Gonzalez-Rabade et al., 2011). One of the
main advantages of plants is that their tissues provide a natural
environment for antigen encapsulation, which protects the
antigen from degradation (Limaye et al., 2006; Hayden et al.,
2012). In this way, when the plant tissue is digested, a sufficient
quantity of antigen can be captured from the mucous mem-
branes and stimulate an immune response (Berinstein et al.,
2005; Kapusta et al., 2010). For this reason, plants are an ideal
vehicle for oral vaccine administration.
Previously, a His-tagged truncated version of the T. gondii
GRA4 antigen (residues 163–345), transiently expressed in
tobacco leaves using vacuum agroinfiltration, has been found
to be able to react with seropositive human sera (Ferraro et al.,
2008). Compared to nuclear transformation, chloroplast trans-
formation offers many advantages, including high levels of
transgene expression likely due to a high copy number, absence
of epigenetic effects, transgene containment via maternal inher-
itance and multigene expression in a single transformation event
(Lo¨ssl and Waheed, 2011). In addition, tobacco chloroplast–
derived vaccines are able to induce neutralizing antibodies against
human or animal infections (Molina et al., 2005; Ferna´ndez-San
Milla´n et al., 2008). More importantly, proteins expressed in
plastids have been found to be stable in the gut and efficiently
transported to the circulatory system (Limaye et al., 2006). For
these reasons, the main goal of this study was to explore the
expression of T. gondii GRA4 antigen by chloroplast transforma-
tion in tobacco plants, and to determine the ability of this antigen
to induce protection in a T. gondii murine infection model when
administered orally without any adjuvant.
Results
Integration of the GRA4 sequence into the tobacco
plastid genome
The GRA4 sequence (corresponding to amino acids 183–345;
Mevelec et al., 1998) was expressed from the plastid constitutive
promoter and 5′UTR of the psbA gene and translationally fused to
the 3′-end of the first 45 nucleotides of the GFP sequence, which
has been shown to be a desirable downstream box (DB) to
improve protein accumulation in tobacco chloroplasts (Farran
et al., 2010). The chimeric gene was cloned into the chloroplast
transformation vector pAF-TDHIS for insertion between the trnI
and trnA genes in the tobacco plastome (Figure 1a). This vector
contains a chimeric aadA gene as the selectable marker, which
provides spectinomycin resistance for selecting stable transfor-
mants. Additionally, the pAF-TDHIS vector allows the translational
fusion of the transgene to the 42-amino acid tetramerization
domain (TD) from the human transcription factor p53 (Ortigosa
et al., 2010) and introduces a C-terminal 7xHis tag.
The pAF-TDHIS-GRA4 construct was introduced into tobacco
(cv. Petite Havana) plastids by biolistic transformation (Daniell,
1997). The stable integration of the foreign gene into the
chloroplast genome and the homoplasmy of the transformed
plants were confirmed by Southern blot analysis. After two
rounds of selection, total leaf DNA from the regenerated plants
was digested with the BglII restriction enzyme, which cuts in two
positions flanking the insertion site and in one position in the
psbA promoter (Figure 1a). The 0.8-kb probe P1, which is
homologous to the flanking regions trnI and trnA (Figure 1a),
was used. Two of the three transplastomic lines analysed showed
the expected hybridization pattern and revealed the absence of
residual copies of the wild-type plastome (Figure 1b, lanes 1 and
3). To ultimately confirm homoplasmy, seeds from the T0
generation were germinated in vitro on spectinomycin-selective
medium. Lack of segregation for spectinomycin resistance in the
T1 generation demonstrated homoplasmy (data not shown). Line
1 was selected for further studies.
Expression and quantification of the GRA4183-345 protein
The recombinant protein GRA4 in transformed chloroplasts
(chlGRA4) was detected by Western blot with an anti-GRA4
polyclonal antibody. Leaves from four plants were analysed
(Figure 2a). Each sample showed a specific 34-kDa band (the
GRA4 antigen fused to the DB and the TD) (Figure 2a). This band
(a)
(b)
Figure 1 Integration of chimeric GRA4 gene into the plastid genome and
homoplasmy verification. (a) Map of the wild-type and GRA4-transformed
plastid genomes. The transgenes are targeted to the intergenic region
between trnI and trnA. The Gra4 expression cassette includes the psbA
promoter and 5′-untranslated region (PpsbA) and the psbA terminator
(TpsbA) from tobacco. A downstream box (DB) with the first 15 amino
acids of the soluble modified GFP protein was used. The GRA4 sequence
was translationally fused to the 42 amino acid tetramerization domain (TD)
from the human transcription factor p53. The selectable marker gene
aadA is driven by the ribosomal RNA operon promoter (Prrn). The
expected sizes of DNA fragments in Southern blot analysis with the
restriction enzyme BglII are indicated. The 0.8-kb fragment (P1) of the
targeting region for homologous recombination was used as probe.
Arrows indicate the direction of transcription. (b) Southern blot analysis of
three independent transplastomic tobacco lines is shown. Total DNA was
digested with BglII and probed with P1.
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showed an electrophoretic mobility higher than the E. coli-
derived and purified GRA4 (rGRA4) as a consequence of the
translational fusions described above (Figure 2a). ChlGRA4 accu-
mulation in these plants was approximately 6 lg/g of fresh
weight (FW) (equivalent to 0.2% of total protein) (Figure 2a), as
estimated by Western blot analysis using rGRA4 (Martin et al.,
2004), previously quantified. No protein was detected in samples
extracted from wild-type control plants.
The effect of plant age on chlGRA4 protein expression was
analysed in plants growing in the glasshouse at 45 and 90 days.
Soluble and insoluble proteins were extracted from fully devel-
oped leaves, and chlGRA4 expression was analysed by Western
blot (Figure 2b). The specific 34-kDa band was observed in 45
and 90-day-old plants mainly in the insoluble fraction, and no
degradation products were detected (Figure 2b). The higher
expression level after 90 days of culture in the glasshouse in
relation to that after 45 days indicates that chlGRA4 is stable in
the stroma of the chloroplast.
Leaves from chlGRA4 over-expressing tobacco plants were
excised 120 days after transplanting, lyophilized, ground to
powder and stored at 4 °C. ChlGRA4 accumulation in lyophilized
plant leaf stocks was estimated by Western blot analysis using a
dilution series (10, 20, 40, 60 and 80 ng) of rGRA4 (Martin et al.,
2004), previously quantified as reference (Figure S1). The amount
of chlGRA4 protein accumulated in the chloroplast was estimated
to be approximately 12 lg/g of lyophilized weight. Lyophilized
material was chosen for oral administration to mice.
Immunogenicity of chloroplast-derived GRA4
Considering that T. gondii infects the host through the gut
mucosa, the efficacy of oral immunization with transplastomic
plants expressing chlGRA4 was analysed. C57BL/6(H-2d) mice
were immunized orally with leaf extracts from chlGRA4 plants
(GRA4 group), leaf extracts from wild-type plants (control group)
or PBS buffer (PBS group). To determine whether this vaccination
strategy was able to promote protection against T. gondii
infection, 2 weeks after the last boost, mice were challenged
by intragastric gavage with a nonlethal dose of Me49 tissue cysts
and individual parasitemia levels were assessed 1 month later. An
important decrease in the brain cyst burden (59%) was observed
as compared to the control and PBS groups (Figure 3). No
differences in the parasitemia levels were observed between
these two control groups (Figure 3).
Systemic immune response generated by chlGRA4
To examine whether leaf extracts from chlGRA4 plants admin-
istered orally were able to elicit a systemic immune response,
blood samples were obtained 14 days after the immunization
schedule was completed and the specific IgG antibodies against
rGRA4 were determined by direct ELISA (Figure 4). As shown in
Figure 4, GRA4-specific serum IgG antibodies were detected in all
mice receiving chlGRA4 with titres of 1000 (Figure S2), while
mice vaccinated with leaf extracts from wild-type plants or PBS
did not display significant titres. To investigate the dominant Th
pattern stimulated following immunization, GRA4-specific IgG
isotypes were determined by direct ELISA. Significant levels of
IgG2b and IgG1 were observed only in chlGRA4-vaccinated mice
with titres of 500 for IgG2b and 250 for IgG1 (Figure 4b,
(a) (b)
Figure 2 Chloroplast-derived GRA4 protein expression. (a) Western blot indicating the expression of chlGRA4 from four independent transplastomic
plants. GRA4 polyclonal antibody specific for rGRA4 protein was used. Wild-type (WT) protein served as the control. Lanes 1, 2, 3 and 4: Protein samples
from four independent transplastomic plants (transgenic plants 1, 2, 3 and 4, respectively) extracted from 100 mg of leaf fresh weight. 20 and 40 : 20 and
40 ng rGRA4, respectively. (b) Western blot analysis of chlGRA4 protein expression in soluble (S) and insoluble (IN) fractions. Proteins extracted from
100 mg of leaf fresh weight of homogenous stocks of five transplastomic (chlGRA4) plants and wild-type (WT) plants 45 and 90 days after transplanting
were loaded in lanes. 100 : 100 lg of rGRA4. Coomassie blue-stained gels were used as controls of the protein loading. M: prestain molecular weight
protein marker (Fermentas). The arrow indicates the chlGRA4 protein.
Figure 3 Protection of C57BL/6(H-2d) mice against Toxoplasma infec-
tion. Eight- to ten-week-old mice (eight mice per group) were immunized
on days 0, 7, 14, 21 and 28 by oral administration. Two weeks after the
last boost, mice were challenged by gavages with 20 cysts of the Me49
strain (LD50). Thirty days after the challenge, the number of brain cysts in
mice was determined. Control: mice vaccinated with leaf extracts from
wild-type plants; GRA4: mice vaccinated with leaf extracts from chlGRA4
plants; PBS: mice vaccinated with buffer PBS. Statistical analysis was
performed by one-way analysis of variance (ANOVA) using the Bonferroni’s
multiple comparison test. Results are expressed as the means ± SEM and
represent one of two similar experiments. Different letters indicate
statistically significant differences (P < 0.001 GRA4 vs. control and PBS).
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Figure S2). Then, the ability of the vaccination protocol to
promote antigen-specific cellular response was assessed in the
spleen. The concentrations of Th1- or Th2-associated cytokines
were quantified in supernatants of spleen cells restimulated
in vitro with excretory-secretory antigens (ESA). Spleen cells of
mice immunized with chlGRA4 produced significant levels of IFN-
c, IL10 and IL-4 when compared to the control and PBS groups
(Figure 5). These results show that oral immunization with leaf
extracts from chlGRA4 plants induces a mixed Th1/Th2 response
at the systemic level.
Mucosal immune response generated by chlGRA4
To examine whether oral administration of leaf extracts from
chlGRA4 plants is able to induce antibody-specific response at
mucosal levels, intestinal lavages were collected 45 days after
the last immunization, and the presence of GRA4-specific
secretory immunoglobulin A (sIgA) was evaluated by ELISA.
ChlGRA4-vaccinated mice elicited significant levels of GRA4-
specific sIgA compared to the control and PBS groups (Figure 6).
Then, the ability of this oral vaccination protocol to promote
antigen-specific cellular response was assessed in gut-associated
lymphoid tissue (GALT). Forty-five days after the immunization
schedule was completed, we estimated the concentration of
Th1- and Th2-associated cytokines by capture ELISA in superna-
tants of mesenteric lymph node cells stimulated in vitro with
ESA. A significant increase in the amount of secreted IFN-c, IL10
and IL-4 was observed in mice immunized with chlGRA4 when
compared to the control and PBS groups (Figure 7). These
results show that a vaccination protocol based on oral admin-
istration of leaf extracts from chlGRA4 plants triggers a strong
mucosal response characterized by the presence of GRA4-
specific sIgA and secretion of Th1- and Th2-associated cytokines
in the GALT.
Discussion
A live toxoplasma vaccine based on the attenuated S48 strain of
the parasite has been registered and is currently used in veterinary
medicine (Hiszczynska-Sawicka et al., 2011). However, it is not
suitable for humans due to the risks for breakthrough infection
(Hiszczynska-Sawicka et al., 2011). Therefore, new approaches to
vaccine development using subunit vaccines based on T. gondii
antigens have been widely initiated (Jongert et al., 2009).
Plant expression systems have been intensively studied to
provide an attractive alternative for oral vaccine production (Paul
and Ma, 2010). In the present work, the GRA4 antigen of
T. gondii was expressed in tobacco plants. Chloroplast transfor-
mation was carried out to improve the expression level of the
heterologous protein. Previously, the yields of GRA4 in tobacco
infiltrated leaves were in the order of 0.01% of total soluble
protein, which represents around 0.2 lg/g of fresh weight
(Ferraro et al., 2008). Here, the chlGRA4 expression levels in
the transplastomic plants were up to 6 lg/g of fresh weight (or
0.2% of total protein). As expected, chloroplast transformation
allowed a significant 30-fold increase in GRA4 protein accumu-
lation in the plant. In addition, recombinant protein levels were
stable over the whole life cycle of the plants. However, chlGRA4
levels were not as high as the usual figures in plastid transfor-
mation. Given that chlGRA4 seems to be stable in the chloroplast,
low expression levels could be due to an inefficient translation
initiation, despite the use of a DB that has been proven to be
useful for protein accumulation (Farran et al., 2010). The
combination of a DB with a particular ORF may alter mRNA
folding and thus affect translation mediated by the DB, suggest-
ing that empirical optimization is required for each ORF. Gray
et al. (2011) demonstrated the specific effects of three DBs in the
expression level of beta-glucuronidase in tobacco chloroplasts.
GRA4 is a target antigen for both mucosal and systemic
immune responses, and therefore, it is a valuable candidate to be
used in oral vaccination strategies (Bout et al., 1995; Mevelec
et al., 1998). To our knowledge, this is the first report that tested
the immunogenicity of GRA4 antigen in an oral vaccination
approach without the use of any adjuvant. It was previously
shown that oral administration of chloroplast-derived vaccine
antigens produced in tobacco and lettuce conferred combined
protection against malaria and cholera (Davoodi-Semiromi et al.,
2010).
Oral administration of adjuvant-free chlGRA4 was enough to
elicit an immune response capable of inducing partial protection
against T. gondii infection measured as a marked reduction in
brain cyst loads. Similar results were obtained with the rGRA4
protein administrated intramuscularly in combination with adju-
(a) (b)
Figure 4 Determination of specific anti-chlGRA4 humoral response in orally vaccinated C57BL/6(H-2d) mice. Two weeks after the immunization schedule
was completed, blood samples (eight mice per group) were obtained and anti-GRA4-specific antibodies were determined by ELISA. (a) Specific total IgG
and (b) IgG isotype in sera from mice vaccinated with leaf extracts from wild-type plants (control), leaf extracts from chlGRA4 plants (GRA4) or with buffer
PBS (PBS) were determined in duplicate. Mouse sera were diluted 1 : 100 for GRA4-specific antibodies determination (nonsaturating dilutions). Results are
expressed as the mean of the OD630 ± SEM and are representative of two experiments. Statistical analysis was performed by one-way analysis of variance
(ANOVA) using the Bonferroni’s multiple comparison test. Different letters indicate statistically significant differences (P < 0.001 GRA4 vs. control and PBS).
Capital letters correspond to statistical analysis of IgG2b isotype. Lower case letters correspond to statistical analysis of IgG and IgG1 isotype.
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vant-like alum (Martin et al., 2004) or CpG (Sa´nchez et al.,
2011). On the other hand, a protocol based on priming with
plant-derived T. gondii SAG1 protein by oral administration and
intradermal (i.d.) boosting with rSAG1 expressed in bacteria
(Laguı´a Becher et al., 2010) elicited a protection (50%) similar to
that obtained with chlGRA4 (59%). Therefore, the inclusion of
exogenous adjuvants or a rGRA4 i.d. boost or GRA4-SAG1 mixed
plant materials could be implemented to achieve a higher level of
protection against Toxoplasma infection.
Our results also showed that the partial protection against
T. gondii infection was a consequence of the development of
both an effective mucosal and systemic immune response.
Specific mucosal sIgA and serum IgG were produced in mice
immunized with chlGRA4. The high levels of serum IgG would be
indicating a mucosal origin of these antibodies, which was
confirmed by an effective activation of mucosal sIgA. Particularly,
sIgA provide immune protection against Toxoplasma in mucosal
tissues. However, mucosal defences can also be mediated by
cytokines (Dimier-Poisson et al., 2003). Given that the initial
activation of T cells probably occurs in Peyer’s patches and
mesenteric lymph nodes, we investigated the induction of Th1-
and Th2 cytokines in the local lymph nodes. The Th1/Th2 cytokine
levels in chlGRA4-vaccinated mice were higher than in the other
two control groups. These results suggest that the antigen
expressed in the chloroplasts would have been recognized by the
antigen-presenting cells and presented in the gut-associated
lymphoid tissues, resulting in the activation of T helper cells.
chlGRA4 vaccination showed to elicit a mixed IgG2b/IgG1
systemic response with predominance of IgG2b. However,
protection against T. gondii infection is mainly attributed to a
cell-mediated systemic immunity. IFN-c has been shown to be a
major mediator of resistance against toxoplasmosis (Suzuki et al.,
1988; Gazzinelli et al., 1991). Nevertheless, the absence of some
type 2 cytokines such as IL-4 or IL-10 can result in an increase in
the immunopathology or mortality in mice (Gazzinelli et al.,
1996; Henriquez et al., 2010). In this context, restimulation of
spleen cells from the chlGRA4-vaccinated group led to the
production of IFN-c, IL-4 and IL-10. The higher levels of
production of IFN-c compared with those of IL-4 and the higher
levels of serum IgG2b over IgG1 indicate that a Th1-mediated
predominant T-cell response was generated. The presence of
large amounts of IL-10 in restimulated splenocytes from chlGRA4-
immunized mice suggests that this vaccination protocol also
elicits a feedback modulation of this predominant Th1 response.
Finally, oral chlGRA4 vaccination also induced the production of
IL-4, a Th2 cytokine, suggesting a B-cell contribution to the
protection obtained after T. gondii infection in vaccinated mice.
Figure 5 Cytokine productions by spleen cells in orally vaccinated C57BL/
6(H-2d) mice. Forty-five days after the immunization schedule was
completed, spleen and lymph node cells were isolated from mice (five
mice per group) and stimulated in vitro with excretory-secretory antigens
(ESA) (10 lg/mL). Values for IFN-c, IL-4 and IL-10 were measured at 72 h
of culture. Results are mean cytokine concentrations in spleen cells from
the five mice of each experimental group. Control: mice vaccinated with
leaf extracts from wild-type plants; GRA4: mice vaccinated with leaf
extracts from chlGRA4 plants; PBS: mice vaccinated with buffer PBS.
Results from one of two similar experiments are shown and are expressed
as the mean ± SEM Statistical analysis was performed by one-way analysis
of variance (ANOVA) using the Bonferroni’s multiple comparison test.
Different letters indicate statistically significant differences (P < 0.001
GRA4 vs. control and PBS).
Figure 6 Determination of specific anti-chlGRA4 sIgA in intestinal lavages
of orally vaccinated mice. Forty-five days after the immunization schedule
was completed, intestinal lavage samples (five mice per group) were
obtained and antibody concentration was determined by ELISA. Results are
expressed as the percentage of GRA4-specific IgA with respect to the total
IgA present in the sample ± SEM and are representative of two experi-
ments. The total mean IgA values ± SEM for the different groups were as
follows: GRA4, 32.58 ± 2.52 ng/mL; control group, 11.22 ± 1.60 ng/mL;
and PBS group, 19.54 ± 1.58 ng/mL. Statistical analysis was performed by
one-way analysis of variance (ANOVA) using the Bonferroni’s multiple
comparison test. Different letters indicate statistically significant differences
(P < 0.001 GRA4 vs. control; P < 0.01 GRA4 vs. PBS).
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These results are supported with the T and B epitopes mapped in
the GRA4 sequence (Mevelec et al., 1998). However, additional
adjuvants present in the plant material could be contributing
with the modulation of the immune response observed in
mice vaccinated with chlGRA4 (Gonzalez-Rabade et al., 2011;
Corigliano et al., 2011).
In conclusion, our findings suggest that chloroplast-derived
GRA4 is able to induce a protective immune response against
Toxoplasma infection in mice that correlates with a mucosal and
systemic balanced Th1/Th2 response. This indicates that chlGRA4
displays a good potential for toxoplasmosis control by oral
vaccination. Moreover, plant expression of GRA4 as well as SAG1
(Clemente et al., 2005; Laguı´a Becher et al., 2010) provides an
excellent possibility for the development of a multicomponent
vaccine against Toxoplasma.
Experimental procedures
Genetic engineering of the chloroplast expression
vectors
The GRA4 sequence was amplified by PCR from the pQ-
GRA4 vector (Martin et al., 2004) using the primers
5′-cccgggCTGCAGTTGAGACAACAGTC-3′ (upstream) and
5′-ctcgagCTCTTTGCGCATTCTTTCC-3′ (downstream), which
introduces the SmaI and XhoI sites, respectively. The SmaI-XhoI
GRA4 fragment was cloned into the pSK-GFP:EDA plasmid
(Farran et al., 2010), which allows the translational fusion of
GRA4 to the first 15 amino acids of the soluble modified GFP
protein (GenBank accession no. U_70495). The resulting
pSK-GFP:GRA4 vector was digested by SalI and XhoI, and the
generated fragment, which also contains the promoter and 5′UTR
of the tobacco psbA gene, was introduced into the tobacco
chloroplast transformation vector pAF-TDHIS (Ortigosa et al.,
2010) previously digested by SalI, to produce pAF-GRA4.
Bombardment and regeneration of chloroplast
transgenic plants
Gold microprojectiles coated with pAF-GRA4 plasmid DNA were
bombarded into in vitro grown tobacco (Nicotiana tabacum var.
Petite Havana) leaves using the PDS1000/He (Bio-Rad, Hercules,
California) biolistic device, as previously described (Daniell,
1997). After bombardment, leaves were incubated in the dark
for 2 days at 28 °C. Leaves were then cut into small pieces
(approximately 5 9 5 mm) and placed adaxial side up on
regeneration medium (RMOP) in Magenta vessels (Sigma, St.
Louis, MO) containing 500 mg/L spectinomycin dihydrochloride
as the selecting agent. The regenerated spectinomycin-resistant
shoots were subjected to a second round of selection under the
same conditions. These regenerated plants were then trans-
planted and grown in a greenhouse for homoplasmy confirma-
tion and seed production.
Southern blot analysis
Total plant DNA (10 lg) was digested with BglII, separated on a
0.8% (w/v) agarose gel and transferred to a nylon membrane.
The digestion by BglII and BamHI of the chloroplast vector
generated a 0.8-kb probe (P1) homologous to the flanking
sequences (Figure 1a). Probe labelling and hybridization were
performed using the chemiluminescent AlkPhos direct labelling
and detection system (GE Healthcare, Buckinghamshire, UK).
After homoplasmy confirmation by Southern analysis, seeds were
harvested and germinated in vitro on spectinomycin-selective
medium. The T1 seedlings were isolated and cultured for 4 weeks
in MS medium (Sigma). Finally, plants were transferred to pots
and grown in a greenhouse for further analysis.
Protein extraction and Western blot analysis
Leaf samples (100 mg) were ground in liquid nitrogen, homog-
enized in Laemmli buffer 29 (Laemmli, 1970) and the extract
heated at 100 °C for 5 min. To separate soluble and insoluble
protein fractions, the pulverized samples (100 mg) were homog-
enized in a soluble protein extraction buffer (20 mM NaPO4,
250 mM NaCl, 0.1% Triton X-100, Ferna´ndez-San Milla´n et al.,
Figure 7 Cytokine productions by lymph node cells in orally vaccinated
C57BL/6(H-2d) mice. Forty-five days after the immunization schedule was
completed, spleen and lymph node cells were isolated and stimulated
in vitro with excretory-secretory antigens (ESA) (10 lg/mL). Values for
IFN-c, IL-4 and IL-10 were measured at 72 h of culture. Results are mean
cytokine concentrations in lymph node cells from five mice per experi-
mental group. Control: mice vaccinated with leaf extracts from wild-type
plants; GRA4: mice vaccinated with leaf extracts from chlGRA4 plants;
PBS: mice vaccinated with buffer PBS. Results from one of two similar
experiments are shown and are expressed as the mean ± SEM Statistical
analysis was performed by one-way analysis of variance (ANOVA) using the
Bonferroni’s multiple comparison test. Different letters indicate statistically
significant differences (P < 0.001 GRA4 vs. control and PBS).
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2007). After centrifugation at 10 000 g, the soluble fraction
(supernatant) and insoluble fraction (pellet) were homogenized in
Laemmli buffer 29. Proteins were separated by SDS-PAGE (15%
gel) and transferred onto polyvinylidene fluoride membranes
(PVDF; GE Healthcare) using an Electro-transfer unit (Bio-Rad).
The membranes were sequentially incubated with rabbit poly-
clonal anti-GRA4 antibody (1 : 500) and alkaline phosphatase
conjugated goat anti-rabbit IgG (1 : 5000; Sigma). After wash-
ing, the reaction was developed by the addition of nitroblue
tetrazolium/5-bromo- 4-chloro-3-indolyl phosphate (NBT/BCIP)
substrate (Promega, Fitchburg, Wisconisn). Prestained protein
(Fermentas, Burlington, ON, Canada) was included in Western
blots as molecular weight markers. To estimate the GRA4
accumulation in tobacco leaves, E. coli-derived and purified
GRA4 (rGRA4) of known concentration was also separated by
SDS-PAGE (15% gel), detected by Western blot and used as a
standard to build a calibration curve. Amounts of GRA4 in leaf
extracts were determined by comparison with the rGRA4
calibration curve using the ‘Gel-Pro analyzer’ software (Media
Cybernetics, Rockville, MD).
Animals
Female C57BL/6(H-2d) mice were bred and housed at the animal
facilities of the Biotechnology Research Institute (IIB), National
University of General San Martin (UNSAM), Buenos Aires,
Argentina, and used at 8–10 weeks of age. All procedures
requiring animals were performed in agreement with institutional
guidelines and approved by the Independent Ethics Committee
for the Care and Use of Experimental Animals of the National
University of General San Martin (C.I.C.U.A.E., IIB-UNSAM, 09/
2011).
Oral immunization of mice
In all cases, mice were deprived of food and water for 2 h prior to
each immunization and were gavaged with 83 mg of lyophilized
powder resuspended in a final volume of 200 lL of PBS 19
buffer. Mice from GRA4 group were orally immunized with five
doses of transplastomic leaf extracts homogenized in PBS 19
buffer, without enrichment or purification, containing the equiv-
alent of approximately 1 lg of chlGRA4 at 1-week intervals. The
control group received five doses of wild-type leaf extracts
homogenized in PBS 19 buffer, while the PBS group was
immunized with five doses of PBS 19 buffer. Eight and five mice
per experimental group were used in the challenge infection
experiments and cytokine analysis, respectively.
Measurement of antibody responses
Two weeks after the last immunization, blood was collected from
the tail vein and sera were stored at 20 °C until analysed for the
presence of specific antibodies. Pre-immune serum samples were
used as negative controls.
Antigen-specific antibodies were analysed by enzyme-linked
immunosorbent assay (ELISA) as previously described (Clemente
et al., 2005; Laguı´a Becher et al., 2010). Briefly, each well of 96-
well microtitre plates (Immuno Plate Maxisorp; Nunc, Rochester,
NY) was coated overnight at 4 °C with 5 lg/mL of rGRA4 diluted
in 0.05 M carbonate buffer (pH 9.6). Rat anti-mouse immuno-
globulin G (IgG)–horseradish peroxidase conjugate (1 : 5000) was
used as a secondary antibody (Sigma), and rat anti-mouse IgG1-
or IgG2a-horseradish peroxidase conjugates (1 : 3000) (Pharm-
ingen) were used for isotype analysis. Immune complexes were
revealed with trimethylbenzidine substrate (TMB, One-Step;
Invitrogen, Carlsbad, CA), and optical density was read at
630 nm with an automatic ELISA reader (Dynatech MR4000).
Sera were used at 1 : 50–1 : 8000 dilutions. To attain a
comparative analysis of IgG profiles, serum samples were used
at a 1 : 100 dilution. The negative control serum samples
included in the assay displayed values lower than the cut-off.
On the other hand, 45 days after the last immunization, five
mice were sacrificed and intestinal lavages were obtained by
flushing the organs with several aliquots of PBS supplemented
with 50 mM EDTA, 5% fetal bovine serum (FBS, GIBCO,
Carlsbad, CA) and 10mM PMSF with a final volume of 1 mL.
Lavages were then centrifuged to remove debris (10 min at
3000 g), and supernatant fluids were stored at 80 °C. The
amount of total and GRA4-specific IgA present in intestinal
lavages was determined by ELISA as previously described by
Rharbaoui et al. (2002). To establish the IgA standard curve,
plates coated with goat anti-mouse IgA (Pharmingen) as capture
antibody were further incubated with serial dilutions of purified
mouse IgA (Pharmingen). As secondary antibody, biotinylated
goat anti-mouse IgA (Pharmingen) was used and plates were
developed with trimethylbenzidine substrate (TMB, One-Step;
Invitrogen) and optical density was read at 630 nm with an
automatic ELISA reader (Dynatech MR4000). GRA4-specific IgA
was analysed by a direct ELISA with GRA4 as the coating antigen,
as described above, and specific amounts were calculated using
the IgA standard curve described before. To compensate for
variations in the efficiency of recovery of secretory antibodies
between animals, the results were normalized and expressed as
percentage of GRA4-specific IgA with respect to the total
amount of IgA present in the sample.
Cytokine analysis
Spleens and mesenteric lymph nodes were aseptically removed
from five mice per group 45 days after the last immunization.
Single-cell preparations were obtained by crushing spleens
through stainless steel meshes followed by suspension in eryth-
rocyte lyses buffer (0.15 M NH4Cl, 1.0 M KHCO3, 0.1 mM EDTA,
pH 7.2). The viability of the cells used in the experiments was
always higher than 80%, as measured by trypan blue exclusion
(Sigma). The cells were then suspended in RPMI 1640 medium
(Life Technologies, Carlsbad, CA) supplemented with 10% FBS
(GIBCO), 2b-mercaptoethanol (final concentration, 5 9 105 M),
penicillin (100 U/mL) and streptomycin (100 lg/mL). Superna-
tants from cultured splenocytes and lymph cells (10 9 106/mL)
were collected after 72 h of stimulation with excretory-secretory
antigens (ESA) of T. gondii (10 lg/mL) and stored at 70 °C.
Cytokine production was measured in supernatants at 72 h (IFN-
c, IL-4 and IL-10) by capture ELISA commercial kits (Pharmingen;
BD Biosciences, Sandiego, CA). The sensitivity limits for the assays
were 20 pg/mL for IFN-c, 50 pg/mL for IL-10 and 10 pg/mL for IL-
4. At least two independent ELISAs were performed for each
sample.
Challenge infection
Mice (eight per experimental group) were orally infected with 20
Me49 tissue cysts (sublethal dose) 2 weeks after the last immuni-
zation.Micewere observed daily formortality. Onemonth after the
challenge, mice were sacrificed and their brains removed. Each
brain was homogenized in 2 mL of PBS with a Dounce tissue
grinder. The mean number of cysts per brain was determined by
observation under an optical microscope, by counting four samples
of 20 lL aliquots of each homogenized brain.
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Statistical analysis
Statistical analysis was carried out with the Prism 5.0 Software
(GraphPad, San Diego, CA) using one-way analysis of variance
(ANOVA). A Bonferroni’s test was carried out to compare means.
Values of P < 0.05 were considered significant.
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